r-health venture (GSK 63.5% controlling interest), Novartis agrees to buy GSK's oncology unit for as much as $16B, Novartis to sell vaccines unit to Glaxo for $7.1B, Novartis to sell Animal Health unit to Eli Lilly for — $5.4B. And Philips is currently trading -7.0% after missing estimates due to HC +

qtr with sales increase & positive view (trading +5%) Demand Media soared 20% on better than expected ql report as revs up & boosted 2012 outlook Glaxo to begin hostile offer for Human Genome Sciences (HGS1) at $13/share (HGSI closed $14.62) Green Mountain strips founder Robert Stiller of chairman

line invested $5 million in SetPoint, and its bioelectronics R. & D. unit now has partnerships =ith 26 independent research groups in six countries. Glaxo has also established = $50 million fund to support the science of bioelectronics and is offering a =rize of $1 million to the first team that can de

ard of directors of Glaxo Wellcome plc. From 1988 to 1995 Jim was Vice President, Research and Senior Vice-President R & D for the U.S. subsidiary of Glaxo. During his nearly 13 years with the Company, he oversaw the discovery, development and/or registration of over 20 products marketed by GSK, includin